Farlong Holding Corporation (AFA)
Farlong Holding will go public soon, but the exact IPO date is still unknown.
IPO Price
$4.00
Shares Offered
4,000,000
Deal Size
$16.00M

Company Description

Farlong is a science-driven healthcare and wellness company pioneering innovative solutions and personalized health approaches.

Our vertically integrated brands provide actionable insights and personalized healthcare data, products, and services to help individuals proactively improve and maintain their health.

We develop product formulations and engage contract manufacturers to produce our proprietary supplements, which we then market and distribute.

Our brands engage in the sale of dietary supplements, encompassing herbal products through various sales arrangements.

Farlong Holding Corporation
Country United States
Founded 1999
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 15
CEO Jackson Kwok

Contact Details

Address:
4010 Valley Blvd, Suite 101
Walnut, CA 91789
United States
Phone (909) 468-9215
Website farlong.com

Stock Details

Ticker Symbol AFA
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
IPO Price $4.00
CIK Code 0002054964
Employer ID 99-1138388
SIC Code 2833

Key Executives

Name Position
Jackson Kwok Chief Executive Officer and Director of the Company and Chief Executive Officer of Longstar
Chiwen “Claire” Wang Chief Financial Officer and Director of the Company and Chief Financial Officer and Director of Longstar
Russell Morgan Director Nominee of the Company
Stephanie Chang Director Nominee of the Company
Zhiliang Zhou Director Nominee of the Company

Latest SEC Filings

Date Type Title
Oct 30, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Sep 23, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Aug 29, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Jul 15, 2025 DRS/A [Amend] [Cover] Draft Registration Statement
May 5, 2025 DRS [Cover] Draft Registration Statement